top of page

FDA Said It Needed Overall Survival. Then It Said No. What the Ivonescimab Complete Response Letter Tells Us.

Writer: Lexim AI
Lexim AI
4 days ago
6 min read

On Sunday, November 15, one day after its November 14 goal date, the FDA sent Summit Therapeutics a complete response letter (CRL) for ivonescimab plus platinum-containing chemotherapy in EGFR-mutated, locally advanced or metastatic non-small cell lung cancer after prior EGFR tyrosine kinase inhibitor therapy. Summit disclosed it that morning and filed an 8-K the next day. The application cannot be approved in its present form.

Two weeks ago, in anticipation of this decision, we laid out what each possible outcome would teach other sponsors. This is the outcome in which FDA's written position held, and the reasoning in the letter, as Summit has relayed it, is worth reading closely because it is narrower and more specific than the headline suggests.


What FDA said

According to Summit's release, FDA wrote that it cannot approve the application because substantial evidence of effectiveness is not established without a statistically significant improvement in overall survival (OS). It also said that a progression-free survival (PFS) benefit, without a statistically significant OS improvement, does not support a positive benefit-risk profile for this application.

Those are two different arguments, and the order matters. The first is about the legal evidentiary standard. For a biologics license, FDA must find substantial evidence of effectiveness from adequate and well-controlled investigations, and the letter says that standard is not met without a significant OS result in this setting. The second is a benefit-risk statement: a gain in PFS, on its own, does not outweigh the risks. In our earlier piece we described a possible path in which a near-miss on OS could be weighed within a benefit-risk judgment. The letter, as described, forecloses that path for this application by resting on the effectiveness standard first.

The CRL applies to this BLA, not to ivonescimab's wider development program. Summit's release said no FDA-approved regimen in this setting has demonstrated a statistically significant OS benefit, and presented that as context for the unmet need. FDA concluded that the context did not make HARMONi's PFS result sufficient. Summit's release did not describe what additional evidence FDA requested, a resubmission plan, or timing.


The numbers FDA was looking at

HARMONi randomized 438 patients 1:1 and had two primary endpoints: PFS by independent review and OS. The PFS result was not close to the margin. Median PFS was 6.8 versus 4.4 months, with a hazard ratio of 0.52 (95% confidence interval 0.41 to 0.66). OS was the other primary endpoint. Median OS was 16.8 versus 14.0 months, a hazard ratio of 0.79 (95% CI 0.62 to 1.01; p=0.057), short of the pre-specified threshold.

The safety profile adds context for the benefit-risk statement. Grade 3 or higher treatment-related adverse events were 50.0% with ivonescimab versus 42.2% with chemotherapy alone, and serious treatment-related adverse events were 28.0% versus 15.1%. Summit's description of the letter does not attribute the CRL to safety, but safety data are part of the balance a PFS-only argument must carry.

Summit pointed to an updated analysis with a June 2026 data cutoff, reporting a hazard ratio of 0.76 in the full population and in both Asian and Western patients. It described this as a post hoc analysis from longer follow-up, and its release did not give confidence intervals or other statistical detail for it. In the primary analysis, the hazard ratio in Western patients had been about 0.98, when their median follow-up was 9.2 months, compared with 32.7 months for Asian patients. In the updated analysis, Western median follow-up reached 23.2 months.


Why a later analysis could not rescue the filing

It is tempting to read the 0.98-to-0.76 movement as proof that the early number was an artifact of immature data, and that may be true. But a regulator evaluating a pre-specified efficacy endpoint is bound to the analysis the trial was designed around. Three features of the updated analysis limit what it can do.

  • It was not the pre-specified test. The primary OS analysis followed the statistical plan, including how it controlled the type I error rate. A later cut, described as post hoc, does not inherit that control, and looking at a trial repeatedly until a boundary is crossed inflates the chance of a false positive.

  • Maturity cuts both ways. Longer follow-up can reveal a real late separation of the curves, but it can also change which patients and which subsequent therapies drive the result. Without confidence intervals or the full analysis plan, a reviewer cannot tell which is happening.

  • A hazard ratio is an average. If the benefit appears late, the hazard ratio can mask periods when the curves overlap. FDA's August 2025 draft guidance on assessing OS in oncology trials also flags protocol-specified crossover as something that can complicate interpretation of OS, which is part of why OS is treated with caution in designs that allow it.

None of this means the updated result is meaningless. It may support further study, and Summit is continuing development. It does mean that it was never going to substitute for a significant primary result, and FDA's letter, as relayed, treats it that way.


Reading the decision against FDA's other signals

FDA's August 2025 draft guidance, Approaches to Assessment of Overall Survival in Oncology Clinical Trials (docket FDA-2024-D-5850), recommends that randomized oncology trials be designed to assess OS so that potential harm can be evaluated, and emphasizes OS as a pre-specified safety endpoint when it is not the primary endpoint. That guidance sits in the background of this decision, and it points in a consistent direction: FDA wants OS data to carry real weight, even when PFS looks strong.

HARMONi made OS a primary endpoint, which raised the stakes in one direction. Read as a safety check, the OS result is reassuring, since the point estimate favors ivonescimab and the interval's upper bound sits at 1.01. Read as a test of the effectiveness requirement FDA had stated to the sponsor in advance, it fell short. The CRL resolves which reading governs for this application. It does not claim that ivonescimab lacks activity, and, as relayed, FDA did not dispute that PFS improved.


What happens next

Summit can request a Type A meeting to discuss the letter, which FDA generally aims to hold within about 30 days of a request. A resubmission would be classified as either Class 1 (a two-month review goal) or Class 2 (six months), and the content FDA specifies in the letter determines which applies. FDA has published complete response letters since September 2025, so the full text may become available and would answer what evidence FDA says could change its view.

Separately, Summit and Akeso are running HARMONi-3, comparing ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line NSCLC. Initial results in the squamous cohort could come by the end of this year, with non-squamous results expected in the first half of 2027. Those trials have different designs and endpoints, and they will be judged on their own data.


What other sponsors should take from it

  • A requirement FDA states in writing is the bar. FDA told Summit that a statistically significant OS improvement was necessary. When the trial missed narrowly, the stated requirement was applied as written. Plan on that basis, and if your results may fall short, raise it with FDA before filing, not after.

  • Design for the OS question from the beginning. When OS is a primary or key endpoint, the number of events, follow-up duration, crossover rules, and regional enrollment pace all determine whether the analysis will be mature enough when you need it.

  • Regional maturity is a design choice. HARMONi enrolled roughly 62% of its patients in Asia and 38% elsewhere, and the two groups matured at very different speeds. A multiregional trial should plan for how the population most relevant to U.S. practice will be followed.

  • Unmet need does not lower the evidentiary standard by itself. Summit's argument that no regimen in this setting has shown an OS benefit was acknowledged and not accepted as a substitute.

  • Treat updated analyses as supportive, not curative. Share them with FDA, but build the filing on the pre-specified analysis.

The decision also sends a message to a broader field. Several PD-1 and VEGF bispecific programs are in development; none is approved in the United States, and their sponsors will read this letter closely when they plan registrational trials. They will take less from it about the drug class than about the endpoint: when a trial names OS as a primary endpoint, a strong PFS result is not an alternative.


Sources: Summit Therapeutics, press release (November 15, 2026) and Form 8-K (filed November 16, 2026); Healio, FDA rejects ivonescimab (November 16, 2026); OncLive and CancerNetwork coverage of the complete response letter (November 16, 2026); BioPharm International (November 16, 2026); Fierce Biotech and pharmaphorum coverage (November 2026); HARMONi primary analysis, Lancet Oncology 2026;27(9):1094-1109; updated HARMONi OS analysis, WCLC 2026 (Passaro et al.); FDA draft guidance, Approaches to Assessment of Overall Survival in Oncology Clinical Trials (August 2025; docket FDA-2024-D-5850); FDA CDER annual report on publication of complete response letters.

Comments


bottom of page